Related references
Note: Only part of the references are listed.Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program
Melanie Care et al.
MOLECULAR ONCOLOGY (2021)
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making
Soledad Jorge et al.
GYNECOLOGIC ONCOLOGY (2020)
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
Ewa Przybytkowski et al.
BMC CANCER (2020)
Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes
Lorena Incorvaia et al.
CANCERS (2020)
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients
Lorena Incorvaia et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Costs and benefits of tumor testing for BRCA mutations in high-grade serous ovarian cancer as a triage for confirmatory genetic testing
J. S. Kwon et al.
GYNECOLOGIC ONCOLOGY (2019)
Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy
Caterina Fumagalli et al.
CANCERS (2019)
An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice
Gillian Ellison et al.
HUMAN MUTATION (2018)
ClinVar: improving access to variant interpretations and supporting evidence
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas
Robbert D. A. Weren et al.
HUMAN MUTATION (2017)
Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients
Ettore Capoluongo et al.
SEMINARS IN ONCOLOGY (2017)
Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study
Cornelia Meisel et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2017)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
Jonathan A. Ledermann et al.
LANCET ONCOLOGY (2016)
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing
Andrea Mafficini et al.
ONCOTARGET (2016)
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist et al.
JAMA ONCOLOGY (2016)
Whole-genome characterization of chemoresistant ovarian cancer
Ann-Marie Patch et al.
NATURE (2015)
Toward understanding and exploiting tumor heterogeneity
Ash A. Alizadeh et al.
NATURE MEDICINE (2015)
Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families
C. F. Singer et al.
WIENER KLINISCHE WOCHENSCHRIFT (2015)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Jonathan Ledermann et al.
LANCET ONCOLOGY (2014)
BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups
T. Safra et al.
ANNALS OF ONCOLOGY (2013)
BRCA1/2 Sequence Variants of Uncertain Significance: A Primer for Providers to Assist in Discussions and in Medical Management
Noralane M. Lindor et al.
ONCOLOGIST (2013)
A Comprehensive Focus on Global Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer
Fatemeh Karami et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
Shiyu Zhang et al.
GYNECOLOGIC ONCOLOGY (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Bryan T. J. Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
Elizabeth M. Swisher et al.
CANCER RESEARCH (2008)
Assessing Pathogenicity: Overview of Results from the IARC Unclassified Genetic Variants Working Group
Sean V. Tavtigian et al.
HUMAN MUTATION (2008)
Sequence Variant Classification and Reporting: Recommendations for Improving the Interpretation of Cancer Susceptibility Genetic Test Results
Sharon E. Plon et al.
HUMAN MUTATION (2008)
Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations
M Gallardo et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Share Paper
